Biotin (Vitamin) : Physiology, Evidence, and Clinical Translation

Biotin: The Carboxyl Carrier for Carbon Dioxide Fixation, Gene Regulation, and Epithelial Integrity

Biotin, vitamin B7, is a water-soluble vitamin that serves as the obligate cofactor for a small family of five mammalian carboxylase enzymes that catalyze the fixation of bicarbonate into organic substrates. These carboxylases are not peripheral metabolic enzymes; they are the gatekeepers of the tricarboxylic acid cycle anaplerosis, the first committed step of fatty acid synthesis, the degradation of odd-chain fatty acids and branched-chain amino acids, and the metabolism of leucine. Biotin is covalently attached to the epsilon-amino group of a specific lysine residue in the active site of each carboxylase, forming biocytin, a modification that converts the apocarboxylase to its active holoenzyme. The biotinylated lysine acts as a flexible arm that swings the carboxyl group from the site of bicarbonate activation to the site of substrate carboxylation. Beyond its classical cofactor function, biotin has emerged as a regulator of gene expression at the level of transcription and as a nutrient whose status is determined by a complex interplay between dietary intake, the intestinal microbiota, and the activity of biotinidase, the enzyme that recycles biotin from the biocytin of degraded carboxylases. This monograph is written for the clinician and scientist who seek to understand biotin not as a cosmetic supplement for hair and nails, but as a micronutrient whose deficiency, though rare, produces a distinctive syndrome of periorificial dermatitis, alopecia, and neurological deterioration, and whose pharmacological administration, at supraphysiological doses, has been investigated for the treatment of multiple sclerosis and for the modulation of the transcriptome.

---

Part 1. The Structural and Chemical Identity of Biotin

Biotin is a heterocyclic, sulfur-containing monocarboxylic acid composed of a tetrahydroimidizalone ring fused to a tetrahydrothiophene ring, with a valeric acid side chain attached to the thiophene ring. The chemical formula is C10H16N2O3S. The bicyclic ring system, the ureido ring and the thiophane ring, is the functional core of the molecule. The ureido ring is the site of bicarbonate activation and carboxyl transfer. The valeric acid side chain is the linker that is covalently attached to the lysine residue of the apocarboxylase, a reaction catalyzed by holocarboxylase synthetase. Biotin is a white, crystalline solid that is stable to heat, light, and oxidation, but it is susceptible to degradation by strong acids and alkalis.

The stereochemistry of biotin is essential to its function. The naturally occurring form is D-biotin, and the three asymmetric carbons in the bicyclic ring system are in the specific configuration that orients the ureido ring for catalysis. The biological activity of biotin is confined to the D-isomer; L-biotin and the various synthetic analogs are inactive or inhibitory.

1A. The Biosynthetic Impossibility and the Dietary Sources

Mammals lack the enzymes to synthesize the biotin ring system. Biotin is synthesized by bacteria, fungi, and plants from pimeloyl-CoA, a seven-carbon dicarboxylic acid, through a pathway that involves the enzymes 7-keto-8-aminopelargonic acid synthetase, 7,8-diaminopelargonic acid aminotransferase, dethiobiotin synthetase, and biotin synthase. This pathway is absent in humans. Biotin is therefore a vitamin, and the recommended adequate intake for adults is 30 micrograms per day.

Dietary sources rich in biotin include liver, egg yolk, soybeans, nuts, and certain vegetables such as Swiss chard and spinach. The biotin in these foods is predominantly protein-bound, either as free biotin or as biocytin, the biotin-lysine residue that is the product of proteolytic digestion of the holocarboxylases in the food. Egg white contains avidin, a tetrameric glycoprotein that binds biotin with an extraordinarily high affinity, one of the strongest non-covalent interactions in nature, with a dissociation constant of approximately 10 to the power of negative 15 molar. Avidin is denatured by cooking, and the consumption of large quantities of raw egg whites over a prolonged period produces a biotin deficiency by preventing the absorption of dietary biotin.

1B. The Absorption, Transport, and Cellular Uptake of Biotin

Dietary biotin, whether free or as biocytin, is liberated from its protein matrix by pancreatic proteases. Biocytin is hydrolyzed by biotinidase, a brush border enzyme, to release free biotin and lysine. Free biotin is absorbed in the jejunum by a saturable, carrier-mediated process, the sodium-dependent multivitamin transporter (SMVT), which also transports pantothenate and lipoate. The SMVT is a high-affinity, low-capacity transporter that is expressed on the apical membrane of the enterocyte and on the plasma membrane of peripheral tissues.

Once in the plasma, biotin is transported in both a free and a protein-bound form, primarily to albumin and to the biotin-binding proteins of the plasma. The uptake of biotin from the plasma into cells is mediated by the SMVT, which recognizes the valeric acid side chain of the molecule. The concentration of free biotin in the plasma is very low, in the nanomolar range, reflecting the efficiency of the cellular uptake and the retention of the vitamin by the biotin-dependent carboxylases.

---

Part 2. The Carboxylase Biology: The Biotin-Dependent Reactions

The five mammalian biotin-dependent carboxylases are acetyl-CoA carboxylase (ACC), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), 3-methylcrotonyl-CoA carboxylase (MCC), and geranyl-CoA carboxylase. Each enzyme catalyzes a two-step reaction: the ATP-dependent carboxylation of the biotin prosthetic group, which is attached to the biotin carboxylase domain, and the transfer of the carboxyl group from carboxybiotin to the acceptor substrate, which is bound to the carboxyltransferase domain.

2A. Acetyl-CoA Carboxylase: The First Step of Fatty Acid Synthesis

ACC catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the first and rate-limiting step of de novo fatty acid synthesis. Malonyl-CoA is the two-carbon donor for the fatty acid synthase complex, and its concentration is a determinant of the rate of fatty acid synthesis. Malonyl-CoA is also an allosteric inhibitor of carnitine palmitoyltransferase-1 (CPT-1), the enzyme that transports long-chain fatty acyl-CoAs into the mitochondrion for beta-oxidation. The malonyl-CoA signal, generated by ACC, integrates the control of fatty acid synthesis and fatty acid oxidation, and biotin is the cofactor that sits at the center of this metabolic switch.

There are two isoforms of ACC in humans. ACC1 is cytoplasmic and is expressed in lipogenic tissues, primarily the liver and adipose tissue, where it generates the malonyl-CoA for fatty acid synthesis. ACC2 is mitochondrial and is expressed in oxidative tissues, including the heart and skeletal muscle, where its malonyl-CoA product is localized to the mitochondrial outer membrane and inhibits CPT-1, controlling the entry of fatty acids into the mitochondrion. A biotin deficiency reduces the activity of both ACC isoforms, impairing fatty acid synthesis and altering the regulation of fatty acid oxidation.

2B. Pyruvate Carboxylase: The Anaplerotic Gateway to the TCA Cycle

PC catalyzes the carboxylation of pyruvate to oxaloacetate, a reaction that is the major anaplerotic pathway for the tricarboxylic acid cycle. Oxaloacetate is the four-carbon acceptor that condenses with acetyl-CoA to form citrate, and its concentration is a determinant of the flux through the TCA cycle. In the liver and kidney, the oxaloacetate generated by PC is also the substrate for gluconeogenesis, the synthesis of glucose from three-carbon precursors including pyruvate, lactate, and amino acids. A biotin deficiency impairs PC activity, reducing the capacity for gluconeogenesis and for the maintenance of the TCA cycle intermediate pool.

2C. Propionyl-CoA Carboxylase: The Degradation of Odd-Chain Fatty Acids and Branched-Chain Amino Acids

PCC catalyzes the carboxylation of propionyl-CoA to methylmalonyl-CoA, a reaction in the catabolic pathway of odd-chain fatty acids, the amino acids isoleucine, valine, methionine, and threonine, and the side chain of cholesterol. Methylmalonyl-CoA is subsequently racemized and isomerized to succinyl-CoA, which enters the TCA cycle. A defect in PCC activity, whether from biotin deficiency or from an inborn error of the enzyme, leads to the accumulation of propionic acid and its metabolites, which are toxic to the central nervous system and produce a metabolic acidosis.

2D. 3-Methylcrotonyl-CoA Carboxylase: The Leucine Catabolic Pathway

MCC catalyzes the carboxylation of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a reaction in the mitochondrial degradation of leucine. A deficiency of MCC activity, whether inherited or acquired from biotin deficiency, leads to the accumulation of 3-methylcrotonyl-CoA and its metabolite, 3-hydroxyisovaleric acid, which is excreted in the urine and is a marker of biotin status.

2E. Geranyl-CoA Carboxylase: A Recent Addition to the Biotin-Dependent Family

Geranyl-CoA carboxylase catalyzes the carboxylation of geranyl-CoA, a C10 isoprenoid, in the mevalonate-independent pathway of isoprenoid synthesis. The metabolic significance of this reaction in human physiology is not fully defined.

---

Part 3. The Non-Carboxylase Biology of Biotin: Gene Regulation, Histone Modification, and Immunity

The discovery that biotin influences the expression of a significant fraction of the human genome, and that this effect is not mediated by the carboxylase enzymes, has opened a new dimension of biotin biology that is independent of its classical cofactor function.

3A. Biotinylation of Histones and the Regulation of Chromatin

Holocarboxylase synthetase, the enzyme that covalently attaches biotin to the apocarboxylases, also biotinylates specific lysine residues on histones, particularly histone H4. Biotinylated histones are enriched in the heterochromatin, the condensed, transcriptionally silent fraction of the genome, and the biotinylation mark is associated with the repression of gene transcription. The debiotinylation of histones, catalyzed by biotinidase, reverses the mark. The biotinylation and debiotinylation of histones is a dynamic, cycling modification that is distinct from the irreversible biotinylation of the carboxylases, and it provides a mechanism by which the biotin status of the cell can directly influence the chromatin landscape and the pattern of gene expression.

The specific genes that are regulated by the biotin status of the histone code include those encoding the enzymes of carbohydrate and lipid metabolism, the insulin receptor, and the cytokines that control the immune response. A biotin deficiency alters the biotinylation of histones and changes the expression of these genes, a transcriptional effect that may contribute to the metabolic and immunological manifestations of biotin deficiency.

3B. Biotin and the Regulation of the Transcriptome

Transcriptomic analyses of cells cultured in biotin-deficient versus biotin-sufficient media have demonstrated that the expression of a large number of genes, perhaps as many as 10 percent of the genome, is altered by biotin status. The affected genes span a wide range of functional categories, including intermediary metabolism, cell signaling, and immune function. The mechanism is not solely the biotinylation of histones; biotin also influences the activity of specific transcription factors, including the nuclear factor kappa-B (NF-kappaB) and the specificity protein 1 (SP1) transcription factors. The binding of biotin to NF-kappaB, or the biotinylation of a component of the NF-kappaB signaling complex, has been proposed as a mechanism by which biotin suppresses the expression of pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-1. This anti-inflammatory effect of biotin, if it operates in vivo, could be a component of the therapeutic effect of high-dose biotin in the central nervous system.

3C. Biotin and the Immune System

The expression of the interleukin-2 receptor and the production of interferon-gamma by T lymphocytes are sensitive to biotin status. Biotin deficiency in animal models impairs the function of the thymus and the spleen, reducing the number and activity of natural killer cells and T lymphocytes. The significance of these observations for human immune competence is not fully established, but the potential for biotin to modulate the immune response is a consideration in the context of the high-dose biotin therapy that is being investigated for multiple sclerosis.

---

Part 4. The Clinical Taxonomy of Biotin Deficiency and Pharmacological Use

Biotin deficiency is rare but produces a characteristic and recognizable clinical syndrome. The pharmacological use of high-dose biotin is a separate clinical domain that has emerged from the observation that biotin can influence the biology of the central nervous system and the immune system.

4A. Biotin Deficiency: The Periorificial Dermatitis, Alopecia, and Neurological Triad

The clinical syndrome of biotin deficiency is defined by a triad of dermatological, neurological, and psychiatric manifestations. The dermatitis is a distinctive, periorificial, scaly, and erythematous rash that involves the eyes, nose, mouth, and perineum, a distribution that is similar to the rash of zinc deficiency. The alopecia is a diffuse thinning of the scalp hair, and the hair that remains is depigmented and brittle. The neurological manifestations include hypotonia, lethargy, developmental delay in infants, and, in adults, depression, hallucinations, and a paresthesia of the extremities.

The causes of biotin deficiency include the prolonged consumption of raw egg whites, which contain the biotin-binding protein avidin; long-term parenteral nutrition without biotin supplementation; severe, generalized malnutrition; and the inborn errors of biotin metabolism, specifically biotinidase deficiency and holocarboxylase synthetase deficiency. These inherited disorders present in infancy with a severe, life-threatening metabolic acidosis, a characteristic organic aciduria that reflects the failure of the biotin-dependent carboxylases, and the dermatological and neurological features of biotin deficiency.

4B. Biotinidase Deficiency and Holocarboxylase Synthetase Deficiency

Biotinidase deficiency is an autosomal recessive disorder caused by mutations in the BTD gene. Biotinidase is the enzyme that releases biotin from biocytin, the product of proteolytic digestion of the holocarboxylases, and it is essential for the recycling of endogenous biotin. A deficiency of biotinidase produces a functional biotin deficiency despite an adequate dietary intake. The clinical presentation is in infancy, with seizures, hypotonia, the characteristic dermatitis, alopecia, and a metabolic acidosis. The diagnosis is made by newborn screening in many jurisdictions, and the treatment is oral biotin at a pharmacological dose of 5 to 20 milligrams per day, which is sufficient to bypass the defect in recycling and to maintain the intracellular biotin pool.

Holocarboxylase synthetase deficiency is an autosomal recessive disorder caused by mutations in the HLCS gene that encodes the enzyme that attaches biotin to the apocarboxylases. The clinical presentation is similar to that of biotinidase deficiency but is often more severe and presents earlier, sometimes in the neonatal period. The treatment is oral biotin at 10 to 20 milligrams per day, which increases the intracellular biotin concentration and drives the residual activity of the mutant synthetase.

4C. High-Dose Biotin in Multiple Sclerosis

The use of high-dose biotin, at doses of 100 to 300 milligrams per day, for the treatment of progressive multiple sclerosis has been investigated in clinical trials. The rationale is twofold. First, biotin is a cofactor for the acetyl-CoA carboxylase that synthesizes malonyl-CoA, the substrate for the fatty acid synthase that produces the myelin lipids. The provision of high-dose biotin could, in theory, support the synthesis of myelin in the oligodendrocytes of the central nervous system and promote the repair of the demyelinated axon. Second, biotin, at these supraphysiological doses, may modulate the transcription of genes involved in the immune response and in the energy metabolism of the neuron and the oligodendrocyte.

A pilot study and a randomized, double-blind, placebo-controlled trial of high-dose biotin in patients with progressive multiple sclerosis reported an improvement in disability, as measured by the Expanded Disability Status Scale (EDSS), in a subset of patients. The effect was modest, and the results have not been consistently replicated in subsequent trials. The use of high-dose biotin in multiple sclerosis is an experimental therapy that is not approved by regulatory agencies and that should be administered only in the context of a clinical trial or under the close supervision of a neurologist who can monitor for the potential for interference with laboratory immunoassays.

---

Part 5. The Evidence Mapped by Quality and Clinical Application

The clinical evidence for biotin is organized around the treatment of biotin deficiency, the management of the inborn errors of biotin metabolism, and the emerging, unproven applications in neurodegeneration and immunology.

5.1. Biotin for the Treatment of Biotin Deficiency and Inherited Metabolic Disease

The evidence is definitive and is the standard of care. The administration of oral biotin at 5 to 20 milligrams per day to patients with biotinidase deficiency or holocarboxylase synthetase deficiency rapidly reverses the metabolic acidosis, the organic aciduria, and the dermatological and neurological manifestations of the disease. The treatment is lifelong, and the response is dramatic and gratifying.

5.2. Biotin and the "Hair, Skin, and Nail" Nutraceutical

The inclusion of biotin in nutraceutical formulations for the health of the hair, skin, and nails is a widespread commercial practice that is based on the observation that biotin deficiency causes alopecia and dermatitis. The evidence for an effect of biotin supplementation, in the absence of a deficiency, on the quality or quantity of hair growth, on the strength of the nails, or on the appearance of the skin is anecdotal and of low quality. A single, uncontrolled study of biotin for brittle nails reported an improvement in nail thickness, but the study was not randomized or blinded. The use of biotin for cosmetic indications is not supported by rigorous clinical evidence, but the safety of the doses that are typically used, 2.5 to 5 milligrams per day, is not in question.

5.3. The Biotin-Immunoassay Interference: A Critical Clinical Consideration

The administration of high-dose biotin, typically at doses of 100 milligrams per day or greater, produces plasma biotin concentrations that are thousands of times higher than the physiological nanomolar range. These concentrations of biotin interfere with the biotin-streptavidin binding chemistry that is the basis for a large number of clinical immunoassays, including those for thyroid-stimulating hormone, troponin, parathyroid hormone, and the serological tests for infectious diseases. The interference can produce falsely elevated or falsely suppressed results, depending on the assay architecture, leading to a misdiagnosis of hyperthyroidism, a missed diagnosis of myocardial infarction, or an erroneous assessment of the response to an infectious disease. The FDA has issued a safety communication on this risk, and every clinician who is considering the use of high-dose biotin, and every clinician who is evaluating a patient who is taking high-dose biotin, must be aware of this potentially life-threatening laboratory artifact.

---

Part 6. A Clinical Dosing Compendium

The dosing of biotin spans four orders of magnitude, from the microgram to the gram.

6.1. Evidence-Based and Guideline-Supported Protocols

Nutritional Supplementation. The adequate intake of 30 micrograms per day is provided by a standard diet and by a multivitamin.

Biotinidase Deficiency and Holocarboxylase Synthetase Deficiency. Oral biotin 5 to 20 milligrams per day, administered as a single daily dose. The dose is titrated to the clinical and biochemical response.

Cosmetic Dosing for Hair and Nails. Oral biotin 2.5 to 5 milligrams per day, a dose that is safe but of unproven efficacy. The cost and the potential for interaction with laboratory tests should be discussed with the patient.

6.2. Theoretical and Postulated Dosing Frameworks

High-Dose Biotin in Progressive Multiple Sclerosis. The dose that has been investigated in clinical trials is 100 to 300 milligrams of biotin per day, administered orally. This dose is three to four orders of magnitude higher than the nutritional requirement. The clinician who prescribes this regimen must inform the patient of the experimental nature of the therapy, must document the informed consent, and must ensure that all clinical laboratories that are processing the patient's samples are aware of the biotin supplementation and are using biotin-interference-free assay methods.

6.3. Universal Principles Governing Biotin Supplementation

The Distinction Between a Nutritional Supplement and a Pharmacological Intervention Is Defined by the Dose. A dose of 30 micrograms to 5 milligrams per day is a nutritional supplement, intended to support the physiological function of the carboxylases. A dose of 100 to 300 milligrams per day is a pharmacological intervention, intended to produce a non-physiological effect on the transcriptome and on the immune system. The safety and efficacy of the pharmacological dose are not established.

Biotin Interferes with Laboratory Assays. This is a universal principle that applies to all patients on high-dose biotin. The interference is a function of the biotin concentration in the plasma, and it can persist for days after the last dose of biotin. The management of the patient on high-dose biotin must include a protocol for the communication of the biotin status to the clinical laboratory and for the interpretation of the results.

Biotin Deficiency Is Rare, but It Is Readily Treatable. The diagnosis of biotin deficiency should be considered in any patient who presents with the triad of periorificial dermatitis, alopecia, and neurological symptoms, particularly if there is a history of raw egg white consumption, long-term parenteral nutrition, or a metabolic acidosis of unknown cause. The response to biotin therapy is rapid and complete, and the failure to make the diagnosis is a missed opportunity for a simple and effective intervention.

---

Part 7. The Unresolved Frontier

Three specific questions define the current limit of biotin science.

What Is the Mechanism of Action of High-Dose Biotin in the Central Nervous System? The hypothesis that biotin supports myelin synthesis by increasing the activity of acetyl-CoA carboxylase is plausible, but it has not been directly demonstrated in the human oligodendrocyte. The alternative hypothesis, that biotin acts as a transcriptional regulator of genes involved in energy metabolism and immune function, is supported by in vitro data but has not been validated in the human brain. The identification of the molecular target of high-dose biotin in the central nervous system is essential to the rational design of a therapeutic agent for multiple sclerosis and other demyelinating diseases.

Can the Biotinylation of Histones Be Targeted for Therapeutic Benefit? The discovery that the biotinylation of histones is a dynamic modification that regulates the expression of genes involved in metabolism and immunity opens the possibility of targeting the enzymes that add or remove the biotin mark for the treatment of metabolic disease or cancer. The holocarboxylase synthetase and the biotinidase that cycle the biotin mark on and off the histones are potential drug targets, but the biology of the biotinylated histone is not sufficiently understood to translate this concept into a therapeutic strategy.

What Is the Role of the Gut Microbiome in Human Biotin Status? The bacteria of the colon synthesize biotin, and the biotin that they produce is absorbed across the colonic epithelium and appears in the systemic circulation. The quantitative contribution of this bacterially derived biotin to the human biotin pool, and the factors that regulate it, are not known. The possibility that the gut microbiome is a significant source of biotin, and that the composition of the microbiome can influence biotin status, is a question that is relevant to the assessment of biotin requirements and to the interpretation of the plasma biotin concentration.

---

Part 8. Synthesis for an Evidence-Based Approach

Biotin is a vitamin whose classical function is the cofactor for a family of five carboxylases that are essential for fatty acid synthesis, gluconeogenesis, and the catabolism of odd-chain fatty acids and branched-chain amino acids. The deficiency of biotin produces a distinctive clinical syndrome of periorificial dermatitis, alopecia, and neurological deterioration, a syndrome that is recognized in the inherited disorders of biotin metabolism and in the acquired deficiency states of raw egg white consumption and parenteral nutrition without biotin supplementation. The treatment of biotin deficiency is simple, safe, and effective, and the diagnosis should not be missed.

The biology of biotin has expanded beyond the carboxylases. The discovery that biotin is a covalent modifier of histones and that the biotin status of the cell influences the expression of a large fraction of the genome has created a new field of biotin research that is distinct from its vitamin function. The investigation of high-dose biotin as a transcriptional modulator in multiple sclerosis is a direct extension of this new biology, and the results, while not definitive, have provided a clinical framework for the investigation of the therapeutic potential of the non-carboxylase functions of the vitamin.

The clinical use of biotin is stratified by the dose. At nutritional doses, it is an essential micronutrient. At intermediate doses, it is a cosmetic supplement of unproven efficacy. At high doses, it is an experimental pharmacological agent with a real potential for toxicity, not from the biotin molecule itself, but from the interference with the laboratory assays that guide clinical decision-making. The clinician who prescribes biotin must be aware of this unique toxicity profile and must manage it proactively. The unresolved questions in biotin science, the mechanism of the central nervous system effect, the role of the microbiome, and the therapeutic potential of the histone biotinylation pathway, are the frontiers that will define the next chapter in the biology of this essential vitamin.